For years, artificial intelligence (AI) in healthcare has been defined more by promise than proof. Pilots have proliferated across clinical and administrative domains, yet a scaled, measurable impact has been elusive. That is starting to change.
Revenue cycle management (RCM) is emerging as one of the first areas where AI is delivering tangible, repeatable impact at scale. Findings from our 2026 Healthcare RCM Survey suggest that adoption is accelerating rapidly and that a clear set of patterns is emerging. We surveyed more than 200 decion-makers and 90 end users at provider organizations from across the US, spanning local/rural independent hospitals, large regional/multi-state health systems, academic medical centers, medical groups, and other outpatient care facilities, including ambulatory surgery centers and urgent care.
AI in revenue cycle is moving from experimentation to early scale
The market is moving decisively beyond experimentation. Across the revenue cycle value chain, roughly 20% to 40% of organizations we surveyed report broad or enterprise-wide use of AI-enabled tools, indicating deployment across a majority of sites, departments, or clinicians rather than confined to isolated pilots.
At the same time, investment is accelerating. Between 70% and 90% of decision-makers expect to increase spending on AI-enabled RCM capabilities over the next three years, with many planning moderate to significant annual growth.
This combination of expanding enterprise adoption and sustained investment confirms that AI in RCM is moving from isolated use cases to being integrated into day-to-day operations.
The no-regret AI investments in revenue cycle are becoming clear
A consistent finding from the survey is the lack of a single dominant use case: while 92% of respondents agree there are no-regret AI investments to pursue, the specific initiatives they consider “no-regret” vary based on organizational priorities.
Ambient documentation, clinical documentation improvement (CDI), coding automation, and electronic prior authorization (ePA) rose to the top. Together, these form a core demand stack for AI in the revenue cycle.
These applications in RCM share several characteristics:
- They integrate into existing workflows rather than requiring full transformation.
- They address long-standing friction points such as documentation burden and coding variability.
- They produce measurable financial impact.
Organizations are seeing meaningful gains with targeted uses of AI improving how clinical complexity is captured, with some studies showing accuracy hit 90% or higher in specific clinical domains. AI is also delivering operational benefits, with studies showing up to nearly 46% reductions in coding time for complex cases. Together, these advances enable health systems to improve the case mix index and recover millions of dollars annually by ensuring coded data more accurately reflects true patient acuity.
Broader market data underscores the momentum: 63% of healthcare organizations have already integrated AI-powered automation into their revenue cycle workflows, and 80% of health systems report actively exploring, piloting, or implementing generative AI tools for RCM, a 38-percentage-point increase in under two years.
What uneven AI adoption means for providers, payers, and investors
Despite these gains, adoption remains uneven. Some organizations are scaling AI across workflows, while others remain in earlier deployment stages. Smaller and community-based providers, in particular, appear to be under-investing in certain capabilities relative to larger systems.
This divergence suggests the potential for a widening gap in performance. As leading organizations scale AI, they are likely to capture compounding benefits in both efficiency and revenue optimization. Over time, this may reshape competitive dynamics across the healthcare ecosystem.
For providers, AI-enabled RCM is quickly becoming a core lever for financial performance. Early adopters are realizing measurable revenue gains and operational efficiencies, while lagging organizations risk falling behind. The priority now is scaling to keep pace with the market.
Smaller and community-based providers must find ways to unlock capacity and budget to keep pace and prioritize deliberately. Providers also need to decide which vendors to work with, whether to pursue best-of-breed or seek a more consolidated vendor model relying on a few key partners. Additionally, providers need to ensure that AI governance and risk management frameworks keep up.
For payers, improved documentation and coding accuracy on the provider side is beginning to translate into real financial and affordability impacts. As providers capture more in documentation and coding, reimbursement levels are increasing, contributing to measurable shifts in cost-of-care trends. In response, payers need to accelerate investments in analytics, payment integrity capabilities, auditing and validation.
However, this is also rapidly proving to be a contentious space between stakeholders. Increasingly, the imperative for payers will be to explore payment models that better align incentives with clinical value and reduce unnecessary complexity in the reimbursement value chain.
For private capital, RCM represents one of the clearest areas of near-term AI value creation in healthcare and remains an attractive space for continued investment. There is, however, some uncertainty to manage, particularly the degree to which point solutions like ambient dictation and coding automation remain separate or begin to integrate into unified solutions. There is also the risk of disintermediation by upstream players, including electronic health record vendors, as they mature equivalent solutions and compete more aggressively for RCM market share. Significant value remains available to investors, but rigorous due diligence at the asset, workflow, and AI-impact levels will be essential to separating real returns from inflated expectations.
AI in healthcare operations has reached a defining moment
The shift from fragmented pilots to scaled deployment, and from theoretical value to measurable impact. marks a pivotal moment in the industry’s adoption of AI at scale.
For leaders across providers, payers, and investors, there’s a clear takeaway: the impact is already here, and the pace of change is accelerating.